IP Library Patent Application 18595873
Patent Application
App. No. 18/595,873

NEUROMODULATION FOR METABOLIC CONDITIONS OR SYNDROMES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/595,873
Abstract

According to some embodiments, a method of treating a subject having diabetes or symptoms associated with diabetes is provided. The method includes delivering a neuromodulation catheter within a vessel (e.g., hepatic artery) having surrounding nerves that innervate the liver (e.g., sympathetic nerves of the hepatic plexus). The method may also include modulating (e.g., disrupting, ablating, stimulating) the nerves by mechanical compression, energy delivery, or fluid delivery.

Claims (34)

1 - 2 . (canceled)

3 . A method comprising:

positioning at least one therapeutic element of a neuromodulation device within a hepatic artery of a subject;

causing at least one of energy or a chemical agent to be delivered by the at least one therapeutic element to nerves proximate the hepatic artery of the subject, wherein the at least one of the energy or the chemical agent is sufficient to ablate at least some of the nerves proximate the hepatic artery;

positioning the at least one therapeutic element of the neuromodulation device within a second artery different than the hepatic artery; and

causing the at least one of energy or the chemical agent to be delivered by the at least one therapeutic element to nerves proximate the second artery, wherein the at least one of the energy or the chemical agent is sufficient to ablate at least some of the nerves proximate the second artery.

4 . The method of claim 3 , wherein the at least one of energy or the chemical agent delivered to nerves proximate the hepatic artery and the nerves proximate the second artery are delivered sequentially.

5 . The method of claim 3 , wherein the at least one of energy or the chemical agent delivered to nerves proximate the hepatic artery and the nerves proximate the second artery are delivered simultaneously.

6 . The method of claim 3 ,

wherein causing the at least one of energy or the chemical agent to be delivered by the at least one therapeutic element to the nerves proximate the hepatic artery comprises causing the at least one of energy or the chemical agent to be delivered to the nerves proximate the hepatic artery over one or more instances of therapy delivery defining a first application time,

wherein causing the at least one of energy or the chemical agent to be delivered by the at least one therapeutic element to nerves proximate the second artery comprises causing the at least one of energy or the chemical agent to be delivered by the at least one therapeutic element to nerves proximate the second artery over one or more instances of therapy delivery defining a second application time,

wherein the first application time is different than the second application time.

7 . The method of claim 3 , wherein causing at least one of energy or the chemical agent to be delivered by the at least one therapeutic element comprises causing energy to be delivered by the at least one therapeutic element.

8 . The method of claim 7 , wherein the energy comprises at least one of radiofrequency energy, high-intensity focused ultrasound energy, low-intensity focused ultrasound energy, electroporation energy, ionizing energy, cryogenic energy, or microwave energy.

9 . The method of claim 3 , wherein causing at least one of energy or the chemical agent to be delivered by the at least one therapeutic element comprises causing the chemical agent to be delivered by the at least one therapeutic element.

10 . The method of claim 9 , wherein the chemical agent comprises at least one of a muscarinic receptor agonist, an anticholinesterase agent, a nicotinic receptor agonist, a nicotine receptor antagonist, a neurotoxin, an alcohol, guanethidine, or zinc sulfate.

11 . The method of claim 3 , wherein:

positioning the at least one therapeutic element within the hepatic artery comprises intravascularly advancing the at least one therapeutic element into the hepatic artery; and

positioning the at least one therapeutic element within the second artery comprises intravascularly advancing the at least one therapeutic element into the second artery.

12 . The method of claim 3 , wherein causing at least one of energy or the chemical agent to be delivered by the at least one therapeutic element to nerves proximate the hepatic artery comprises causing at least one of energy or the chemical agent to be preferentially delivered by the at least one therapeutic element to sympathetic nerves surrounding the hepatic artery.

13 . The method of claim 12 , wherein causing at least one of energy or the chemical agent to be preferentially delivered by the at least one therapeutic element to sympathetic nerves surrounding the hepatic artery comprises causing the at least one therapeutic element to deliver the at least one of energy or the chemical agent in a proximal portion of the hepatic artery.

14 . The method of claim 13 , wherein the proximal portion of the hepatic artery comprises a common hepatic artery.

15 . The method of claim 3 , wherein the neuromodulation device is configured to exert a contact force by the at least one therapeutic element against a wall of the hepatic artery of about 1 g/mm 2 to about 500 g/mm 2 .

16 . The method of claim 3 , wherein the neuromodulation device comprises a catheter comprising a distal portion configured to bend with a bend radius of less than about 10 mm.

17 . The method of claim 3 , wherein the hepatic artery comprises at least one of a common hepatic artery, a proper hepatic artery, a right hepatic artery, or a left hepatic artery.

18 . The method of claim 3 , wherein the hepatic artery comprises a common hepatic artery.

19 . The method of claim 3 , wherein the nerves proximate the second artery innervate one or more of a pancreas, a small intestine, and a kidney.

20 . The method of claim 3 , wherein the nerves proximate the second artery innervate one or more of a pancreas, a stomach, a small intestine, and a kidney.

21 . The method of claim 3 , wherein the nerves proximate the second artery innervate one or more of a pancreas, a stomach, a small intestine, a kidney, adrenal glands, fat tissue, and brown adipose tissue.

22 . A method comprising:

positioning at least one therapeutic element of a neuromodulation device within a first artery of a subject;

causing at least one of energy or a chemical agent to be delivered by the at least one therapeutic element positioned within the first artery to nerves innervating a liver of the subject, wherein the at least one of the energy or the chemical agent is sufficient to ablate at least some of the nerves innervating the liver;

positioning the at least one therapeutic element of the neuromodulation device within a second artery different than the first artery; and

causing the at least one of energy or the chemical agent to be delivered by the at least one therapeutic element positioned in the second artery to nerves innervating an organ different from the liver, wherein the at least one of the energy or the chemical agent is sufficient to ablate at least some of the nerves innervating the organ different from the liver.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2024
From: AZAMIAN, BOBAK ROBERT; COE, JONATHAN ALLEN; VAFAI, SCOTT BRADLEY
To: METAVENTION, INC.
Reel/Frame 066653/0062 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2024
From: METAVENTION, INC.
To: MEDTRONIC IRELAND MANUFACTURING UNLIMITED COMPANY
Reel/Frame 066653/0756 →